Factory Antiasthmatic 99% Pranlukast Powder CAS 103177-37-3 Pranlukast

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A67
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Adult
• State: Powder
• Purity: >99%
• Name: Pranlukast
• Appearance: White Powder
• Assay: 99%
• CAS: 103177-37-3
• OEM: Available
• Sample: Available
• Suitable: Adult
• Function: Pranlukast
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

Product Name	Pranlukast
Appearance	White Powder
CAS NO.	103177-37-3
Molecular Formula	C27H23N5O4
Molecular Weight	481.503

 

Pranlukast is a common respiratory drug, it belongs to asthma drugs , it is the cysteinyl leukotrienes (LTs) receptor antagonist and it can bind to LTC4, LTD4, LTE4 receptors selectively to antagonize their effect . Roles and application are similar to zafirlukast. It is clinically used for the prevention of bronchial asthma. Oral 225mg once, 2 times one day, morning and evening after meal. After taking ,there may be gastrointestinal reactions,or there may be nausea, vomiting, abdominal pain, diarrhea or constipation, sometimes , fever, rash, pruritus and liver function abnormalities such as serum aminotransferase or bilirubin increase are visible . Pregnant women should use with caution , the elderly should take appropriate reductions. This product can not alleviate the onset of asthma.

 

1. Respiratory Inflammation Management: Pranlukast is primarily used for the management of respiratory inflammation associated with allergic conditions, particularly in the treatment of bronchial asthma.
2. Allergic Rhinitis Relief: It can also provide symptomatic relief in patients with allergic rhinitis, helping to reduce nasal congestion, sneezing, and itching caused by allergens.
3. Prevention of Bronchoconstriction: By inhibiting cysteinyl leukotriene receptors, pranlukast effectively prevents bronchoconstriction, a common manifestation of asthma attacks.

1. Cysteinyl Leukotriene Receptor Antagonism: Pranlukast functions by competitively blocking the cysteinyl leukotriene (CysLT) receptors, primarily CysLT1, which are involved in the mediation of bronchoconstriction, mucus secretion, and inflammatory cell infiltration in the airways.
2. Inflammatory Process Modulation: By inhibiting the effects of CysLTs, pranlukast modulates the inflammatory processes in the respiratory tract, reducing airway inflammation and improving overall lung function.
3. Symptomatic Improvement: It leads to symptomatic improvement in patients with asthma and allergic rhinitis, including decreased frequency and severity of asthma attacks, improved breathing, and reduced nasal and ocular symptoms associated with allergies.